EQRx No Longer Seeks To Disrupt Prices In Non-Small Cell Lung Cancer Space

The biotechnology company EQRx no longer seeks to disrupt prices in the non-small cell lung cancer space. This is disappointing news for those who had hoped for lower prices in a therapeutic category that, for the most part, has been sorely lacking real price competition for years.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive